COVID-19 pill cuts hospitalizations and deaths in half, Merck says

Merck and Company
(Image credit: TOM MIHALEK/AFP via Getty Images)

An experimental pill from Merck was shown in a trial to cut the risk of COVID-19 hospitalization and death in half, the company has announced.

The drugmaker said Friday that in a trial, those who received its pill to treat COVID-19, molnupiravir, within five days of experiencing symptoms had half the rate of hospitalization and death as patients who received a placebo, The Associated Press reports. According to Merck, the rate of hospitalizations or deaths was 7.3 percent among those patients who received molnupiravir compared to 14.1 percent for the placebo group.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Brendan Morrow

Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.